Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma

NCT02876978 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Squamous Cell Carcinoma

Interventions

GENETIC: CAR-GPC3 T Cells
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

CARsgen Therapeutics Co., Ltd.